213 related articles for article (PubMed ID: 24694602)
41. Prolonged Release Niosomes For Ocular Delivery of Loteprednol: Ocular Distribution Assessment on Dry Eye Disease Induced Rabbit Model.
Ozdemir S; Uner B
AAPS PharmSciTech; 2024 May; 25(5):119. PubMed ID: 38816667
[TBL] [Abstract][Full Text] [Related]
42. In Vitro and In Vivo Evaluation of Niosomal Formulation for Controlled Delivery of Clarithromycin.
Shilakari Asthana G; Sharma PK; Asthana A
Scientifica (Cairo); 2016; 2016():6492953. PubMed ID: 27293976
[TBL] [Abstract][Full Text] [Related]
43. Gelatinized core liposomes: A new Trojan horse for the development of a novel timolol maleate glaucoma medication.
Hathout RM; Gad HA; Abdel-Hafez SM; Nasser N; Khalil N; Ateyya T; Amr A; Yasser N; Nasr S; Metwally AA
Int J Pharm; 2019 Feb; 556():192-199. PubMed ID: 30553005
[TBL] [Abstract][Full Text] [Related]
44. Development of matrix-membrane transdermal drug delivery system for atenolol.
Gupta SP; Jain SK
Drug Deliv; 2004; 11(5):281-6. PubMed ID: 15742552
[TBL] [Abstract][Full Text] [Related]
45. Dorzolamide Loaded Niosomal Vesicles: Comparison of Passive and Remote Loading Methods.
Hashemi Dehaghi M; Haeri A; Keshvari H; Abbasian Z; Dadashzadeh S
Iran J Pharm Res; 2017; 16(2):413-422. PubMed ID: 28979296
[TBL] [Abstract][Full Text] [Related]
46. Nonionic surfactant-based vesicular system for transdermal drug delivery.
Ghanbarzadeh S; Khorrami A; Arami S
Drug Deliv; 2015 Dec; 22(8):1071-1077. PubMed ID: 24400680
[TBL] [Abstract][Full Text] [Related]
47. Development of a novel niosomal system for oral delivery of Ginkgo biloba extract.
Jin Y; Wen J; Garg S; Liu D; Zhou Y; Teng L; Zhang W
Int J Nanomedicine; 2013; 8():421-30. PubMed ID: 23378764
[TBL] [Abstract][Full Text] [Related]
48. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery.
El-Menshawe SF; Hussein AK
Pharm Dev Technol; 2013; 18(4):779-86. PubMed ID: 21913880
[TBL] [Abstract][Full Text] [Related]
49. Novel ophthalmic timolol meleate liposomal-hydrogel and its improved local glaucomatous therapeutic effect in vivo.
Zhang HH; Luo QH; Yang ZJ; Pan WS; Nie SF
Drug Deliv; 2011; 18(7):502-10. PubMed ID: 21790329
[TBL] [Abstract][Full Text] [Related]
50. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antifungal drug clotrimazole.
Ning M; Gu Z; Pan H; Yu H; Xiao K
Indian J Exp Biol; 2005 Feb; 43(2):150-7. PubMed ID: 15782815
[TBL] [Abstract][Full Text] [Related]
51. Sustained release of intravitreal flurbiprofen from a novel drug-in-liposome-in-hydrogel formulation.
Pachis K; Blazaki S; Tzatzarakis M; Klepetsanis P; Naoumidi E; Tsilimbaris M; Antimisiaris SG
Eur J Pharm Sci; 2017 Nov; 109():324-333. PubMed ID: 28843864
[TBL] [Abstract][Full Text] [Related]
52. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity.
Qumbar M; Ameeduzzafar ; Imam SS; Ali J; Ahmad J; Ali A
Biomed Pharmacother; 2017 Sep; 93():255-266. PubMed ID: 28738502
[TBL] [Abstract][Full Text] [Related]
53. Intranasal niosomes of nefopam with improved bioavailability: preparation, optimization, and in-vivo evaluation.
Abou-Taleb HA; Khallaf RA; Abdel-Aleem JA
Drug Des Devel Ther; 2018; 12():3501-3516. PubMed ID: 30410310
[TBL] [Abstract][Full Text] [Related]
54. Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation.
Khalil RM; Abdelbary GA; Basha M; Awad GEA; El-Hashemy HA
J Liposome Res; 2017 Dec; 27(4):312-323. PubMed ID: 27241274
[TBL] [Abstract][Full Text] [Related]
55. A new vesicle-loaded hydrogel system suitable for topical applications: preparation and characterization.
Carafa M; Marianecci C; Di Marzio L; Rinaldi F; Meo C; Matricardi P; Alhaique F; Coviello T
J Pharm Pharm Sci; 2011; 14(3):336-46. PubMed ID: 21903019
[TBL] [Abstract][Full Text] [Related]
56. Niosomal encapsulation of ethambutol hydrochloride for increasing its efficacy and safety.
El-Ridy MS; Yehia SA; Kassem MA; Mostafa DM; Nasr EA; Asfour MH
Drug Deliv; 2015 Jan; 22(1):21-36. PubMed ID: 24359403
[TBL] [Abstract][Full Text] [Related]
57. Sustained transdermal delivery of human growth hormone from niosomal gel:
Wang L; Wei L; Long W; Zhang Q; Zou Y
J Biomater Sci Polym Ed; 2022 Jun; 33(9):1198-1212. PubMed ID: 35192434
[TBL] [Abstract][Full Text] [Related]
58. Preparation and evaluation of a buflomedil hydrochloride niosomal patch for transdermal delivery.
Akhtar N; Arkvanshi S; Bhattacharya SS; Verma A; Pathak K
J Liposome Res; 2015 Sep; 25(3):191-201. PubMed ID: 25357198
[TBL] [Abstract][Full Text] [Related]
59. Development and in vitro characterization of niosomal formulations of immunosuppressant model drug.
Rehman M; Rasul A; Waqas MK; Khan MI; Sher M
Pak J Pharm Sci; 2018 Nov; 31(6 (Supplementary):2623-2628. PubMed ID: 30587470
[TBL] [Abstract][Full Text] [Related]
60. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor.
Aggarwal D; Pal D; Mitra AK; Kaur IP
Int J Pharm; 2007 Jun; 338(1-2):21-6. PubMed ID: 17300885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
